Results 221 to 230 of about 31,440 (256)

GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes

Circulation, 2022
Nikolaus Marx, Mansoor Husain, Michael Lehrke   +2 more
exaly  

GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects

Frontiers in Endocrinology, 2021
Lijuan Cui, Yunfeng Liu, Cui Lijuan
exaly  

Cardiovascular and mortality outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A meta-analysis with the FREEDOM cardiovascular outcomes trial

Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2022
Matthew M Y Lee, Søren Lund Kristensen, Hertzel C Gerstein   +2 more
exaly  

The Future of the GLP-1 Receptor Agonists

JAMA, 2019
openaire   +2 more sources

GLP-1 receptor agonists and GIP/GLP-1 co-agonists in the treatment of obesity in adolescents and the elderly

Medicina Clínica (English Edition)
Obesity represents a global public health challenge, with specific characteristics and needs in adolescent and elderly populations. GLP-1 (glucagon-like peptide-1) receptor agonists such as liraglutide and semaglutide, as well as the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor co-agonist tirzepatide, have emerged as promising ...
openaire   +2 more sources

GLP-1 receptor agonists and suicidality

BMJ
Peter, Ueda, Björn, Pasternak
openaire   +2 more sources

GLP-1 Receptor Agonist Orforglipron for Adults with Obesity

New England Journal of Medicine, 2023
Sean, Wharton, Manige, Konig
openaire   +4 more sources

GLP-1 Receptor Agonists Help Legs

Diabetes Care
Ronald M. Goldenberg, Subodh Verma
openaire   +2 more sources

Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis

Diabetes Research and Clinical Practice, 2015
Feng Sun, Shuxia Guo, Linong Ji
exaly  

GLP-1 receptor agonists and obesity care

BMJ
Juan V A, Franco, Jen, Manne-Goehler
openaire   +2 more sources